Efficacy of Lanreotide Autogel in MEN1-Related Gastrinoma: A Case Series

#1012

Introduction: GEP NETs, especially gastrinomas, occur in 40-70% of MEN1 patients and represent the main cause of death in these patients.

Aim(s): To investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.

Materials and methods: We report a monocentric series of seven MEN1 patients (3 M, 4 F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at diagnosis, three months after starting lanreotide and then every six months. Five of the seven patients underwent surgery at least three months after starting lanreotide treatment, while two patients refused surgical treatment.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Iacovazzo D

Authors: Iacovazzo D, Lugli F, Bianchi A, Capoluongo E, Lucci-Cordisco E,

Keywords: MEN1, SSA, gastrin,

To read the full abstract, please log into your ENETS Member account.